DK1753723T3 - Substituerede quinolinderivater som mitotiske kinesininhibitorer - Google Patents

Substituerede quinolinderivater som mitotiske kinesininhibitorer

Info

Publication number
DK1753723T3
DK1753723T3 DK05752901T DK05752901T DK1753723T3 DK 1753723 T3 DK1753723 T3 DK 1753723T3 DK 05752901 T DK05752901 T DK 05752901T DK 05752901 T DK05752901 T DK 05752901T DK 1753723 T3 DK1753723 T3 DK 1753723T3
Authority
DK
Denmark
Prior art keywords
substituted quinoline
quinoline derivatives
mitotic kinesin
kinesin inhibitors
compounds
Prior art date
Application number
DK05752901T
Other languages
Danish (da)
English (en)
Inventor
W Wang
R Constantine
L Lagniton
K Bair
Original Assignee
Novartis Vaccines & Diagnostic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines & Diagnostic filed Critical Novartis Vaccines & Diagnostic
Application granted granted Critical
Publication of DK1753723T3 publication Critical patent/DK1753723T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/18—Halogen atoms or nitro radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
DK05752901T 2004-05-21 2005-05-19 Substituerede quinolinderivater som mitotiske kinesininhibitorer DK1753723T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57312004P 2004-05-21 2004-05-21
PCT/US2005/017961 WO2005113507A1 (en) 2004-05-21 2005-05-19 Substituted quinoline derivatives as mitotic kinesin inhibitors

Publications (1)

Publication Number Publication Date
DK1753723T3 true DK1753723T3 (da) 2008-10-20

Family

ID=34970815

Family Applications (1)

Application Number Title Priority Date Filing Date
DK05752901T DK1753723T3 (da) 2004-05-21 2005-05-19 Substituerede quinolinderivater som mitotiske kinesininhibitorer

Country Status (19)

Country Link
US (2) US7452996B2 (https=)
EP (1) EP1753723B1 (https=)
JP (1) JP2008502721A (https=)
CN (1) CN1956960A (https=)
AT (1) ATE404536T1 (https=)
AU (1) AU2005245492A1 (https=)
BR (1) BRPI0511433A (https=)
CA (1) CA2564215A1 (https=)
DE (1) DE602005008953D1 (https=)
DK (1) DK1753723T3 (https=)
ES (1) ES2311992T3 (https=)
HR (1) HRP20080493T3 (https=)
MX (1) MXPA06011958A (https=)
PL (1) PL1753723T3 (https=)
PT (1) PT1753723E (https=)
RS (1) RS50670B (https=)
RU (1) RU2385867C2 (https=)
SI (1) SI1753723T1 (https=)
WO (1) WO2005113507A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311992T3 (es) * 2004-05-21 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.
EP1781674A1 (en) 2004-08-18 2007-05-09 AstraZeneca AB Enantiomers of selected fused pyrimidones and uses in the treatment and prevention of cancer
US8119655B2 (en) 2005-10-07 2012-02-21 Takeda Pharmaceutical Company Limited Kinase inhibitors
US8202837B2 (en) * 2005-11-04 2012-06-19 Glaxosmithkline Llc Methods for administering hypoglycemic agents
SG158147A1 (en) 2006-10-09 2010-01-29 Takeda Pharmaceutical Kinase inhibitors
EP2091926B1 (en) * 2006-11-13 2015-10-21 Novartis AG Substituted pyrazole and triazole compounds as ksp inhibitors
WO2008086122A2 (en) * 2007-01-05 2008-07-17 Novartis Ag Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
FR2940289B1 (fr) * 2008-12-23 2014-09-12 Biopharmed Derives de la classe des hydroxyquinoleines aminees pour le traitement du cancer du pancreas
MY162940A (en) 2009-08-19 2017-07-31 Eisai R&D Man Co Ltd Quinoline derivative-containing pharmaceutical composition
EA201201404A1 (ru) * 2010-04-15 2013-04-30 Новартис Аг Триазолы как ингибиторы кбв (кинезин-белок веретена)
WO2011128388A2 (en) * 2010-04-15 2011-10-20 Novartis Ag Oxazole and thiazole compounds as ksp inhibitors
JP6038128B2 (ja) 2011-06-03 2016-12-07 エーザイ・アール・アンド・ディー・マネジメント株式会社 レンバチニブ化合物に対する甲状腺癌対象及び腎臓癌対象の反応性を予測及び評価するためのバイオマーカー
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
US9458161B1 (en) 2011-11-03 2016-10-04 Vanderblit University TSPO ligands for cancer imaging and treatment
EP2882436A1 (en) * 2012-08-13 2015-06-17 Array Biopharma, Inc. Arry-520 for use in treating cancer in a patient with low aag
PT3524595T (pt) 2014-08-28 2022-09-19 Eisai R&D Man Co Ltd Derivado de quinolina altamente puro e método para produção do mesmo
LT3263106T (lt) 2015-02-25 2024-01-10 Eisai R&D Management Co., Ltd. Chinolino darinių kartumo sumažinimo būdas
KR102662228B1 (ko) 2015-03-04 2024-05-02 머크 샤프 앤드 돔 코포레이션 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합
MX373231B (es) 2015-06-16 2020-05-08 Eisai R&D Man Co Ltd Agente anticancerigeno.
WO2017030146A1 (ja) * 2015-08-19 2017-02-23 エーザイ・アール・アンド・ディー・マネジメント株式会社 胆道癌治療剤
US12220398B2 (en) 2015-08-20 2025-02-11 Eisai R&D Management Co., Ltd. Tumor therapeutic agent
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172087B1 (en) * 1998-06-03 2001-01-09 Gpi Nil Holding, Inc. N-oxide of heterocyclic ester, amide, thioester, or ketone hair growth compositions and uses
CA2369549A1 (en) 1999-04-02 2000-10-12 Robert W. Desimone Aryl and heteroaryl fused aminoalkyl-imidazole derivatives and their use as antidiabetics
US6545004B1 (en) * 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
CZ20021428A3 (cs) 1999-10-27 2002-11-13 Cytokinetics, Inc. Způsoby a kompozice vyuľívající chinazoliny
MXPA03003039A (es) 2000-10-06 2003-10-15 Neurogen Corp Derivados de indola y bencimidazola como moduladores del receptor crf.
NZ526622A (en) 2000-12-11 2006-07-28 Amgen Sf Llc CXCR3 antagonists
WO2002057244A1 (en) 2001-01-19 2002-07-25 Cytokinetics, Inc. Phenothiazine kinesin inhibitors
EP1351671A1 (en) 2001-01-19 2003-10-15 Cytokinetics, Inc. Triphenylmethane kinesin inhibitors
JP2005511581A (ja) 2001-11-07 2005-04-28 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂キネシン阻害剤
WO2003043995A1 (en) 2001-11-20 2003-05-30 Cytokinetics, Inc. Process for the racemization of chiral quinazolinones
US20050107404A1 (en) 2001-12-06 2005-05-19 Fraley Mark E. Mitotic kinesin inhibitors
CA2468156A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Azolopyrimidinone compounds and their use
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
CA2467722A1 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Thienopyrimidinone derivatives as mitotic kinesin inhibitors
WO2003059289A2 (en) 2002-01-10 2003-07-24 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted benzoimidazole analogues
JP2005529076A (ja) 2002-02-15 2005-09-29 サイトキネティクス・インコーポレーテッド キナゾリノンの合成
AU2003249597B2 (en) 2002-03-08 2007-06-28 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors
NZ536190A (en) * 2002-04-17 2007-08-31 Cytokinetics Inc Compounds for treating cellular proliferative diseases by modulating the activity of the mitotic kinesin KSP
RU2004135554A (ru) 2002-05-09 2006-01-20 Цитокинетикс, Инк. (Us) Пиримидиноны, композиции на их основе и способы их использования
EP1553931A4 (en) 2002-05-09 2006-08-30 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1509507A4 (en) 2002-05-23 2006-09-13 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
EP1513820A4 (en) 2002-05-23 2006-09-13 Cytokinetics Inc COMPOUNDS, COMPOSITIONS AND METHODS
EP1515724B1 (en) 2002-06-14 2009-10-21 Merck & Co., Inc. Mitotic kinesin inhibitors
CA2489367A1 (en) * 2002-06-14 2003-12-24 Cytokinetics, Inc. Compounds, compositions, and methods
ATE356804T1 (de) 2002-06-14 2007-04-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
AU2003247891A1 (en) 2002-07-08 2004-01-23 Merck & Co., Inc. Mitotic kinesin binding site
DE60326248D1 (de) 2002-07-17 2009-04-02 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren zur behandlung von zellulären proliferativen erkrankungen
EP1537089A4 (en) 2002-07-23 2008-04-16 Cytokinetics Inc CONNECTIONS, COMPOSITIONS AND PROCEDURES
WO2004018058A2 (en) 2002-08-21 2004-03-04 Cytokinetics, Inc. Compounds, compositions, and methods
EP1554265A4 (en) 2002-09-13 2008-05-07 Cytokinetics Inc COMPOSITIONS, COMPOSITIONS AND M THODES
ES2311992T3 (es) * 2004-05-21 2009-02-16 Novartis Vaccines And Diagnostics, Inc. Derivados de quinolina sustituida com,o inhibidores de cinesina mitotica.

Also Published As

Publication number Publication date
US20050261337A1 (en) 2005-11-24
AU2005245492A1 (en) 2005-12-01
RS50670B (sr) 2010-06-30
EP1753723B1 (en) 2008-08-13
SI1753723T1 (sl) 2009-04-30
HRP20080493T3 (hr) 2009-02-28
RU2385867C2 (ru) 2010-04-10
MXPA06011958A (es) 2006-12-15
US20090028858A1 (en) 2009-01-29
PL1753723T3 (pl) 2009-01-30
PT1753723E (pt) 2008-11-19
JP2008502721A (ja) 2008-01-31
RU2006145336A (ru) 2008-06-27
DE602005008953D1 (de) 2008-09-25
US7452996B2 (en) 2008-11-18
EP1753723A1 (en) 2007-02-21
CN1956960A (zh) 2007-05-02
WO2005113507A1 (en) 2005-12-01
BRPI0511433A (pt) 2007-12-11
CA2564215A1 (en) 2005-12-01
ATE404536T1 (de) 2008-08-15
ES2311992T3 (es) 2009-02-16

Similar Documents

Publication Publication Date Title
DK1753723T3 (da) Substituerede quinolinderivater som mitotiske kinesininhibitorer
MX2007004699A (es) Derivados de indol y bencimidazol.
TW200612958A (en) Substituted imidazole derivatives
WO2008086122A3 (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
TW200626610A (en) Analogs of 17-hydroxywortmannin as PI3K inhibitors
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
EA201200049A1 (ru) 1,3-дизамещенные производные имидазолидин-2-она в качестве ингибиторов cyp 17
ATE495176T1 (de) Spiroindolinon-derivate
PH12012500903A1 (en) N1 - pyrazolospiroketone acetyl-coa carboxylase inhibitors
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
NO20080865L (no) Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
MX2012009186A (es) Pirrolidina-2-carboxamidas sustituidas.
SMT201300109B (it) Imidazopiridazincarbonitrili utili come inibitori di chinasi
TW200801000A (en) Spiroindolinone derivatives
MX2013004733A (es) Inhibidores de n1/n2-lactama acetil-coa carboxilasa.
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
MX2012003982A (es) Pirrolidinas n-substituidas.
EA200900631A1 (ru) Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена)
PA8821301A1 (es) Inhibidores a base de hidroxamato de desacetilasas b
TW200738651A (en) Cyclohexyl sulfonamide derivatives
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
ATE449776T1 (de) Pyrroloä2,3-cüpyridinderivate
WO2007017728A3 (en) Novel heterocyclic compounds
GT200800296A (es) Derivados de ácido fenilacético
EA200901085A1 (ru) Производные циклогексиламида арилкарбоновой кислоты